Email this article COINFECTION BY HEPATITIS B AND HEPATITIS DELTA VIRUSES: MOLECULAR BIOLOGY OF PATHOGENS AND PROSPECTS OF PHARMACOTHERAPY
- Authors: Balmasova I.P.1,2, Sepiashvili R.I.3, Slavyanskaya T.A.3, Malova E.S.3, Sepiashvili Y.R.3
-
Affiliations:
- People's Friendship Universit
- Evdokimov Moscow State Medical-Stomatological University
- People's Friendship University
- Issue: Vol 95, No 2 (2018)
- Pages: 95-102
- Section: REVIEWS
- URL: https://microbiol.crie.ru/jour/article/view/272
- DOI: https://doi.org/10.36233/0372-9311-2018-2-95-102
- ID: 272
Cite item
Full Text
Abstract
Hepatitis delta virus (HDV) is a defective virus and obligate companion of hepatitis B virus (HBV). The clinical significance of HDV and HBV coinfection is associated with more severe forms of acute or chronic viral hepatitis, a higher risk of developing liver cirrhosis and hepatocellular carcinoma compared to BGV-monoinfection. Current knowledge of the molecular biology of pathogens confirms the existence of a very complex relationship between the HBV, HDV, infected hepatocytes and cells of the immune system. Despite the fact that HBV viremia can now be controlled by using nucleoside analogues in the majority of patients, the problem of treating HDV and HBV coinfection is far from being resolved. Fundamental studies in recent years have led to significant progress in understanding the biology of HDV and provide the basis for the development and introduction into clinical practice highly effective antiviral drugs.
About the authors
I. P. Balmasova
People's Friendship Universit; Evdokimov Moscow State Medical-Stomatological University
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
R. I. Sepiashvili
People's Friendship University
Email: noemail@neicon.ru
Russian Federation
T. A. Slavyanskaya
People's Friendship University
Email: noemail@neicon.ru
Russian Federation
E. S. Malova
People's Friendship University
Email: noemail@neicon.ru
Russian Federation
Ya. R. Sepiashvili
People's Friendship University
Email: noemail@neicon.ru
Russian Federation
References
- Богомолов П.О., Воронкова Н.В., Буеверов А.О., Мациевич М.В., Alexandrov A., Wedermeyer H. Первый опыт применения препарата «Myrcludex В» при хроническом гепатите D (Предварительные результаты). Клинические перспективы гастроэнтерологии, гепатологии. 2015, 2: 23-26.
- Балмасова И.П., Сепиашвили Р.И., Малова Е.С. Молекулярная биология вируса гепатита В и иммунопатогенез хронического гепатита В. Журн. микробиол. 2016, 2: 119126.
- Кожанова Т.В., Ильченко Л.Ю., Михайлов М.И. Вирусный гепатит дельта. Существует ли в Российской Федерации проблема дельта-инфекции? Экспериментальная и клиническая гастроэнтерология. 2014, 12 (112): 4-12.
- Сепиашвили Р.И.,Балмасова И.П. Иммунные синапсы: от теории к клинической практике. Молекулярная медицина.2008, 1: 14-22.
- Славянская Т.А.,Сепиашвили Р.И. Роль цитокинов в иммунопатологии. Аллергология и имумнология.2005, 6 (2): 42.
- Abbas Z., Abbas M. Management of hepatitis delta: Need for novel therapeutic options. World J. Gastroenterol. 2015, 21 (32): 9461-9465.
- Alvarado-Mora M.V., Locarnini S., Rizzetto M., Pinho J.R. An update on HDV: virology, pathogenesis and treatment. Antivir. Ther. 2013, 18 (3 Pt. B): 541-548.
- Abbas Z., Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review. World J. Hepatol. 2013, 5 (12): 666-675.
- Aslan N., Yurdaydin C., Wiegand J. et al. Cytotoxic CD4 T cells in viral hepatitis. J. Viral. Hepat. 2006, 13 (8): 505-514.
- Botelho-Souza L.F., Vasconcelos M.P.A. et al. Hepatitis delta: virological and clinical aspects. Virol. J. 2017, 14 (1): 177-191.
- Balmasova I.P., Yushchuk N.D., Mynbaev O.A. et al. Immunopathogenesis of chronic hepatitis B. World J. Gastroenterol. 2014, 20 (39): 14156-14171.
- Fu L., Hu H., Liu Y. et al. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry. Virology. 2017, 505: 1-11.
- Goyal A., Murray J.M. Dynamics of in vivo hepatitis D virus infection. J. Theor. Biol. 2016, 398: 9-19.
- Griffin B.L., Chasovskikh S., Dritschilo A., Casey J.L. Hepatitis delta antigen requires a flexible quasi-double-stranded RNA structure to bind and condense hepatitis delta virus RNA in a ribonucleoprotein complex. J. Virol. 2014, 88 (13): 7402-7411.
- Giersch K., Dandri M. Hepatitis B and delta virus: advances on studies about interactions between the two viruses and the infected hepatocyte. J. Clin. Transl. Hepatol. 2015, 3 (3): 220229.
- Giersch K., Allweiss L., Volz T. et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. J. Hepatol. 2015, 63 (2): 346-353.
- Huang C.-R., Lo S.J. Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus. World J. Gastroenterol. 2014, 20 (40): 14589-14597.
- Higuchi Y., Kawai K., Yamazaki H. et al. The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice. Xenobiotica. 2014, 44 (2): 146-153.
- Huang H.C., Lu H.F., Lai Y.H. et al. Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. Antiviral. Res. 2017, 150: 69-78.
- Huang Y.H., Tao M.H., Hu C.P. et al. Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J. Gen. Virol. 2004, 85 (Pt 10): 3089-3098.
- Jelen M.M., Hosnjak L., Stunf S. et al. Hepatitis D virus infection in Slovenian patients with chronic hepatitis B virus infection: a national prevalence study and literature review. Acta Dermatovenerol Alp. Pannonica Adriat. 2016, 25 (3): 49-53.
- Jin Y., Chen J., Feng Z. et al. The expression of Survivin and NF-kB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma. Tumour Biol. 2014, 35 (10): 9905-9910.
- Le Gal F., Brichler S., Drugan T. et al. Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology. 2017, 66 (6): 1826-1841.
- Lempp F.A., Urban S. Hepatitis delta virus: replication strategy and upcoming therapeutic options for a neglected human pathogen. Viruses. 2017, 9 (7): 172-190.
- Lunemann S., Malone D.F., Grabowski J. et al. Effects of HDV infection and pegylated interferon alpha treatment on the natural killer cell compartment in chronically infected individuals. Gut. 2015, 64 (3): 469-482.
- Li W., Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J. Hepatol. 2016, 64 (1 Suppl.): 32-40.
- Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring. Harb. Perspect. Med. 2014, 4 (11): a021550.
- Rizzetto M. Hepatitis D virus: introduction and epidemiology. Cold Spring. Harb. Perspect. Med. 2015, 5 (7): a021576.
- Rizzetto M. Epidemiology of hepatitis D. Semin Liver Dis. 2012, 32 (3): 211-219.
- Rizzetto M., Ciancio A. The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta. Lancet Infect. Dis. 2015, 15 (10): 1119-1120.
- Sureau C., Negro F. The hepatitis delta virus: Replication and pathogenesis. J. Hepatol. 2016, 64 (1 Suppl): 102-116.
- Sagnelli E., Sagnelli C., Pisaturo M. et al. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J. Gastroenterol. 2014, 20 (24): 76357643.
- Sun X., Sui Q., Zhang C. et al. Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression. Mol. Cancer. Ther. 2013, 12 (12): 2885-2896.
- Taylor J.M. Virology of hepatitis D virus. Semin Liver Dis. 2012; 32 (3): 195-200.
- Williams V., Brichler S., Radjef N. et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J. Gen. Virol. 2009, 90 (Pt. 11): 2759-2767.
- Williams V., Brichler S., Khan E. et al. Large hepatitis delta antigen activates STAT-3 and NF-kB via oxidative stress. J. Viral. Hepat. 2012, 19 (10): 744-753.
Supplementary files
